Calcineurin is a calcium-dependent serine-threonine protein phosphatase. Calcineurin activates the nuclear factor of activated T-cells cytoplasmic (NFAT)c, a transcription factor, by dephosphorylating the protein. The activated NFATc is then translocated into the nucleus, where it upregulates the expression of interleukin 2 (IL-2), which, in turn, stimulates the growth and differentiation of T-cell responses. Calcineurin is the target of a drug class called calcineurin inhibitors (CNI), which includes cyclosporine and tacrolimus. The NFAT transcription factor family consists of five members NFATc1, NFATc2, NFATc3, NFATc4 and NFAT5. Calcium signalling regulates NFATc1-NFATc4. In T cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. The tacrolimus macrolide prevents the dephosphorylation of NFAT by binding to the immunophilin, FK506 binding protein, thereby creating a new complex that reduces peptidylprolyl isomerase activity. This complex inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
Pseudohypoaldosteronism type II (PHA-II) or familial hyperkalaemic hypertension (FHH) is a rare familial renal tubular defect characterized by hypertension and hyperkalaemic, non-anion gap metabolic acidosis in the presence of low renin and aldosterone levels. The molecular basis for most individuals who have PHA-II was linked to loss-of-function mutations in the 'with-no-lysine' kinases (WNK), either WNK1 or WNK4. The WNK kinases comprise a family of serine-threonine protein kinases with unusual placement of the catalytic lysine compared with all other protein kinases. WNK1 or WNK4 regulate chloride cotransporters of the distal nephron and other epithelia. The WNK kinase network and how it regulates sodium balance, potassium homeostasis and blood pressure has recently been reviewed [1, 2] .
To fulfil their regulatory function, the WNK kinases interact with other important kinases, including serum and glucocorticoid-regulated kinase 1, STE20/SPS1-related proline alanine-rich kinase (SPAK) and oxidative stress-responsive protein type 1 (OSR1) kinase. The resultant kinase network regulates the activity of the major sodium and potassium transporters in the distal nephron, including thiazide-sensitive Na-Cl cotransporters (NCC) and the renal outer medullary potassium channel (ROMK). WNK kinases modulate ion transport through two distinct regulatory pathways involving trafficking and phosphorylation. A schematic adapted from recent reviews is given in (Figure 1 ). Mice that lack a catalytically active SPAK are strikingly hypotensive with marked reduction in NCC phosphorylation in the kidney and exhibit reduced Na
À cotransporter (NKCC1) phosphorylation in the vessel wall [2] . SPAK and OSR1 kinases regulate SCL12A transporters with important physiological effects for sodium homeostasis by the kidney, aortic contractility and neuronal excitability. In vivo, SPAK plays a major role in the regulation of blood pressure and represents a potential target for diuretic development.
Rare mutations in WNK kinases cause FHH. However, genetic variations in WNK kinases have been associated with salt-sensitive essential hypertension [1] . Furthermore, heterozygous inactivating mutations in this pathway may protect from hypertension. The pathway has also been implicated in the hypertension associated with Type 2 diabetes mellitus. Acquired syndromes exist that exhibited similar clinical characteristics as PHA-II. One such syndrome occurs in almost every patient undergoing renal transplantation. These patients are invariably treated with CNI. They generally develop hypertension that is commonly associated with non-anion gap (mild) metabolic acidosis and hyperkalaemia.
Recently, Hoorn et al. [3] reported novel findings that may serve to explain the connection. The group hypothesized that CNI induce hypertension by stimulating NCC. They first studied wild-type mice and found that tacrolimus caused salt-sensitive hypertension and increased the abundance of phosphorylated NCC, WNK3, WNK4 and SPAK compared to control mice. They then gave tacrolimus to mice with a gene-disrupted NCC. Tacrolimus could not increase blood pressure in these mice. However, the hypertensive response to tacrolimus was exaggerated in mice overexpressing NCC. The blood pressure increases to tacrolimus were reversed by hydrochlorothiazide treatment. The investigators also included human studies. They showed that kidney transplant recipients treated with tacrolimus had a greater fractional chloride excretion in response to bendroflumethiazide than individuals not treated with tacrolimus. Furthermore, the renal NCC expression was greater as well. The findings make an appealing story that CNIs cause hypertension by inducing a form of acquired PHA-II. Conceivably, hydrochlorothiazide could offer an effective and inexpensive anti-hypertensive treatment for these patients. Strange would be the fact that clinicians did not stumble onto the observations independent of this study. In Europe, physicians generally give these patients furosemide for reasons unclear to this old clinician. Perhaps, furosemide is considered to be a vitamin rather than a drug. Four randomized trials done >30 years ago showed that NCC inhibitors lower blood pressure better than NKCC inhibitors. However, clinicians are difficult to convince; it must be a marketing phenomenon.
Some burning questions remain. How does tacrolimus stimulate NCC activation? What is the relationship between calcineurin and NCC? Presumably, the inhibition of calcineurin is responsible for NCC activation rather than some secondary action of tacrolimus. Does the activation require the prevention of NFAT dephosphorylation? Or does calcineurin interact in some not yet defined way with NCC? To the last point, I consulted with one of the authors (Sebastian Bachmann), who works at the Charité in Berlin. He shared with me Figure 2 . Shown in normal mouse kidney is a remarkable colocalization between calcineurin and NCC. NCC must be dephosphorylated in order to be removed from the plasma membrane. Conceivably, the process is calcineurin dependent and therefore inhibited by tacrolimus.
Also relevant perhaps is a recent study of genomicderived markers in a model of CNI nephrotoxicity [4] . Rats were given generous doses of cyclosporine. The authors identified a group of genes whose expression in rat kidney was correlated with CNI-induced kidney injury. Among the candidates were Slc12a3, which encodes NCC, and the gene encoding kidney-specific Wnk1 (KS-WNK1). The proteins are outlined in Figure 1 and could potentially be involved in the mechanism of CNI-induced nephrotoxicity. Fig. 1 . NCC regulation by WNK kinases. NCC is produced as a monomer that must be inserted into the luminal plasma membrane to become an inactive dimer. WNK4 inhibits this mechanism and directs the NCC monomers (via sortilin and adaptin AP3) to lysosomes for degradation. NCC inactive dimer is activated by SPAK and OSR1 kinase (not shown). WNK3 and WNK1 are the SPAK regulators. They are inhibited by WNK4 and the predominant renal (kidney specific) WNK1 isoform, KS-WNK1. The isoform is a shorter kinase-defective product and serves as a dominant-negative WNK1 regulator (from [1] ). The down-regulation of NCC in rat kidney following CNI treatment was confirmed by immunohistochemical staining, and the down-regulation of KS-WNK1 was confirmed by quantitative real-time polymerase chain reaction. However, the authors did not study the phosphorylated versions of NCC. Furthermore, they conducted a toxicity investigation rather than a blood pressure study.
Most interesting is the report of acquired chimaerism in which a kidney from a patient with Gitelman syndrome (NCC deficiency) was transplanted into a non-Gitelman hypertensive recipient [5] . After transplantation, postural hypotension resulted, necessitating discontinuation of all anti-hypertensive medications used for treatment of CNIinduced hypertension. The authors basically describe an acquired Gitelman syndrome after transplantation. These prescient scholars suggested that their findings supported the potential use of thiazide diuretics in the treatment of CNI-induced hypertension, thereby supporting the work of Hoorn et al. [3] .
